Reta glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking strategy to diabetes management. These innovative therapies operate by mimicking the inherent actions of GLP-1, a hormone released by the gut in response to food. By triggering GLP-1 receptors in the pancreas, these compounds increase insulin secretion and inhibit glu

The management of diabetes is with the emergence of exciting new therapies. Among these, Reta, GLP-1 receptor agonists, Retatrutide, and Trizepatide are gaining significant attention. These medications offer promising approaches for controlling blood sugar levels and potentially improve the lives of individuals living with diabetes. This novel cl